These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 28741901)

  • 1. Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study.
    Béguelin C; Suter A; Bernasconi E; Fehr J; Kovari H; Bucher HC; Stoeckle M; Cavassini M; Rougemont M; Schmid P; Wandeler G; Rauch A;
    Liver Int; 2018 Mar; 38(3):424-431. PubMed ID: 28741901
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of direct antiviral agents in a cohort of cirrhotic HCV/HIV-coinfected patients.
    Navarro J; Laguno M; Vilchez HH; Guardiola JM; Carrion JA; Force L; Cairó M; Cifuentes C; Vilaró J; Cucurull J; Marco A; Roget M; Erice E; Crespo M;
    J Antimicrob Chemother; 2017 Oct; 72(10):2850-2856. PubMed ID: 29091196
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Direct-acting antivirals in hepatitis C virus (HCV)-infected and HCV/HIV-coinfected patients: real-life safety and efficacy.
    Milazzo L; Lai A; Calvi E; Ronzi P; Micheli V; Binda F; Ridolfo AL; Gervasoni C; Galli M; Antinori S; Sollima S
    HIV Med; 2017 Apr; 18(4):284-291. PubMed ID: 27477612
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protease inhibitors to treat hepatitis C in the Swiss HIV Cohort Study: high efficacy but low treatment uptake.
    Schaerer V; Haubitz S; Kovari H; Ledergerber B; Ambrosioni J; Cavassini M; Stoeckle M; Schmid P; Decosterd L; Aouri M; Böni J; Günthard HF; Furrer H; Metzner KJ; Fehr J; Rauch A;
    HIV Med; 2015 Nov; 16(10):599-607. PubMed ID: 26135140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disparities in direct acting antivirals uptake in HIV-hepatitis C co-infected populations in Canada.
    Saeed S; Strumpf EC; Moodie EE; Young J; Nitulescu R; Cox J; Wong A; Walmsely S; Cooper C; Vachon ML; Martel-Laferriere V; Hull M; Conway B; Klein MB;
    J Int AIDS Soc; 2017 Nov; 20(3):. PubMed ID: 29116684
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicted effect of direct acting antivirals in the current HIV-HCV-coinfected population in Spain.
    Poveda E; Vispo E; Barreiro P; de Mendoza C; Labarga P; Fernández-Montero JV; Martin-Carbonero L; Soriano V
    Antivir Ther; 2012; 17(3):571-5. PubMed ID: 22293607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic HCV genotype 1 coinfection.
    Boesecke C; Rockstroh JK
    Curr HIV/AIDS Rep; 2015 Sep; 12(3):326-35. PubMed ID: 26228050
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variation in hepatitis C virus treatment uptake between Canadian centres in the era of direct-acting antivirals.
    Nitulescu R; Young J; Saeed S; Cooper C; Cox J; Martel-Laferriere V; Hull M; Walmsley S; Tyndall M; Wong A; Klein MB;
    Int J Drug Policy; 2019 Mar; 65():41-49. PubMed ID: 30594080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct-acting antiviral treatment against hepatitis C virus infection in HIV-Infected patients - "En route for eradication"?
    Pradat P; Pugliese P; Poizot-Martin I; Valantin MA; Cuzin L; Reynes J; Billaud E; Huleux T; Bani-Sadr F; Rey D; Frésard A; Jacomet C; Duvivier C; Cheret A; Hustache-Mathieu L; Hoen B; Cabié A; Cotte L;
    J Infect; 2017 Sep; 75(3):234-241. PubMed ID: 28579302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland.
    Bachofner J; Valli PV; Bergamin I; Kröger A; Künzler P; Baserga A; Braun DL; Seifert B; Moncsek A; Fehr J; Semela D; Magenta L; Müllhaupt B; Terziroli Beretta-Piccoli B; Mertens J; The Swiss Hepatitis C Cohort Study
    Swiss Med Wkly; 2018; 148():w14560. PubMed ID: 29376557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
    Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
    Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
    Bruno G; Saracino A; Scudeller L; Fabrizio C; Dell'Acqua R; Milano E; Milella M; Ladisa N; Monno L; Angarano G
    Int J Infect Dis; 2017 Sep; 62():64-71. PubMed ID: 28728927
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Assessment of factors affecting response of direct-acting antivirals in chronic hepatitis C patients.
    Jain N; Garg R; Singh GP; Kaur S; Chawla SPS; Padda P
    Ann Afr Med; 2023; 22(4):456-464. PubMed ID: 38358146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Fibrosis in Human Immunodeficiency Virus (HIV)-Hepatitis C Virus (HCV) Coinfection Before and After Sustained Virologic Response: What Is the Best Noninvasive Marker for Monitoring Regression?
    Kronfli N; Young J; Wang S; Cox J; Walmsley S; Hull M; Cooper C; Martel-Laferriere V; Wong A; Pick N; Klein MB;
    Clin Infect Dis; 2021 Aug; 73(3):468-477. PubMed ID: 32504083
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rate and predictors of treatment failure to all-oral HCV regimens outside clinical trials.
    Arias A; Aguilera A; Soriano V; Benítez-Gutiérrez L; Lledó G; Navarro D; Treviño A; Otero E; Peña JM; Cuervas-Mons V; de Mendoza C
    Antivir Ther; 2017; 22(4):307-312. PubMed ID: 27341294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and security of chronic hepatitis C treatment in coinfected patients in real-world.
    Uriarte-Pinto M; Navarro-Aznarez H; De La Llama-Celis N; Arazo-Garcés P; Martínez-Sapiña AM; Abad-Sazatornil MR
    Int J Clin Pharm; 2018 Jun; 40(3):608-616. PubMed ID: 29556931
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Lead-In with Silibinin Prior to Triple-Therapy Translates into Favorable Treatment Outcomes in Difficult-To-Treat HIV/Hepatitis C Coinfected Patients.
    Braun DL; Rauch A; Aouri M; Durisch N; Eberhard N; Anagnostopoulos A; Ledergerber B; Müllhaupt B; Metzner KJ; Decosterd L; Böni J; Weber R; Fehr J;
    PLoS One; 2015; 10(7):e0133028. PubMed ID: 26176696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictive factors of hepatitis C virus eradication after interferon-free therapy in HIV coinfection.
    Domínguez-Domínguez L; Bisbal O; Matarranz M; Lagarde M; Pinar Ó; Hernando A; Lumbreras C; Rubio R; Pulido F
    Eur J Clin Microbiol Infect Dis; 2019 Apr; 38(4):725-734. PubMed ID: 30687869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV infection does not increase the risk of liver complications in hepatitis C virus-infected patient with advanced fibrosis, after sustained virological response with direct-acting antivirals.
    Corma-Gómez A; Morano L; Téllez F; Rivero-Juárez A; Real LM; Alados JC; Ríos-Villegas MJ; Vera-Méndez FJ; Muñoz RP; Geijo P; Macías J; Pineda JA;
    AIDS; 2019 Jun; 33(7):1167-1174. PubMed ID: 30845068
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of new DAA therapy on real clinical practice: a multicenter region-wide cohort study.
    Lanini S; Scognamiglio P; Mecozzi A; Lombardozzi L; Vullo V; Angelico M; Gasbarrini A; Taliani G; Attili AF; Perno CF; De Santis A; Puro V; Cerqua F; D'Offizi G; Pellicelli A; Armignacco O; Mennini FS; Siciliano M; Girardi E; Panella V; Ippolito G;
    BMC Infect Dis; 2018 May; 18(1):223. PubMed ID: 29769038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.